Lightnews — Scholar-powered news

Pauline Funchain

@funchainmd.bsky.social

4.1K followers 1K following 230 posts

Melanoma oncology @Stanford. Study hereditary genetics and irAEs. LA explant in SF via Ohio State, NIH/NHGRI, Harbor UCLA, and Cleveland Clinic. Sports fan, geek and mom. APD Hem/Onc fellowship. ASPirE founder, Checkpoint Now. COI http://bit.ly/43UCDOz

bit.ly

Posts Media Videos Starter Packs

Pinned

Pauline Funchain @funchainmd.bsky.social · Jun 2

Alright y’all - last day of #irAE content at #ASCO25 @aspire-cop.bsky.social @ascocancer.bsky.social

Monday 6/2

11:30a Bi/Multi-specific Antibodies S406
➡️Giuseppe Curigliano
➡️Enriquita Felip
➡️Funda Meric Bernstam

3p Beyond Checkpoint E450b
➡️me 😇
➡️Evan Lipson
➡️Jason Luke

Pauline Funchain @funchainmd.bsky.social · May 30

🗓️ UPDATED! #irAE guide to #ASCO25

Fri 5/30
1p Academic/Commun Tox Care E350
4p ASPirE CoP - join us! E253cd

Sun 6/1
8a Rare/Severe Cases S406
9:30a BiTES Arie
2:30p Tox incl CART E451

Mon 6/2
11:30a Bi/Multi-specific Antibodies S406
1p Beyond Checkpoint E450b

Deets in 🧵👇

Pauline Funchain @funchainmd.bsky.social · May 28

🗓️ Hey irAE fam here’s your #irAE guide to #ASCO25

Fri 5/30
1p Academic/Community Tox Care E350
4p ASPirE CoP - join us! E253cd

Sat 5/31
9:30a BiTES Arie

Sun 6/1
8a Rare and Severe Cases S406
2:30p Tox incl CART E451

Mon 6/2
9:30a Bi and Multi-specific Antibodies S406
1p Beyond Checkpoint E450b

4 5

Pauline Funchain @funchainmd.bsky.social · 21d

Fangirling here - Sumbul Desai VP of Health at Apple, previously worked at Disney, now bringing access to health information to the masses with a small metal and glass box that sits on your wrist #MGR @stanforddeptmed.bsky.social

1 2

Pauline Funchain @funchainmd.bsky.social · 22d

#CCRTP25 cancer immunotherapy session covering the breadth of anti tumor immunity - immune tolerance incited by lymph node involvement @retickerflynn.bsky.social, cytokine conditioning of T cells - A Kalbasi, and synthetic engineering of cytokine receptors - K Daniels @stanford-cancer.bsky.social

Pauline Funchain @funchainmd.bsky.social · 22d

Good morning Redwood City 🌞 Rise and shine to Day 2 of the #CCRTP25 @stanford-cancer.bsky.social Still unbelievable to be colleagues with Dr Ron Levy and see how integrated and committed he is to educating the next generation of cancer researchers

Pauline Funchain @funchainmd.bsky.social · 23d

Great 💎s on GI cancers at #CCRTP25 @stanford-cancer.bsky.social @corsello.bsky.social

-drug discovery w better yield from unexpected hits, then subsequently modified
-negative results so important to publish
-environmental factors like weight most likely culprits of young onset colon cancer

1 1

Pauline Funchain @funchainmd.bsky.social · 23d

Hi! Welcome!

Pauline Funchain @funchainmd.bsky.social · 23d

So far we have talked about non smoking Asian females (lung cancer) and people in their 30s and 40s (colon cancer) and I’m feeling a bit targeted in the worst way 😂 #CCRTP25 @stanford-cancer.bsky.social

Pauline Funchain @funchainmd.bsky.social · 23d

The amazing breath of nicotine products today, with significantly higher amounts of nicotine than cigarettes, covered by keynote speaker Carly Kajiwara from the Halpern-Felsher Lab @stanford-cancer.bsky.social #CCRTP25

Pauline Funchain @funchainmd.bsky.social · 23d

Good morning Redwood City 🌞 Rise and shine for an action packed day at the Comprehensive Cancer Research Training Program @stanford-cancer.bsky.social - Day 1 of 2 for soaking in cancer research 🤓🥳

1 3

Reposted by Pauline Funchain

Stanford Department of Medicine @stanforddeptmed.bsky.social · Jun 12

@mcuban.bsky.social recently brought his business expertise to #StanDOM's Grand Rounds — diagnosing the American healthcare system & proposing a treatment plan.

Watch the full video & read the key takeaways: stanford.io/3FbkfZr

1 3

Reposted by Pauline Funchain

Steven Artandi @stevenartandi.bsky.social · Jun 11

This program reflects our commitment to fostering meaningful partnerships and supporting the next generation of leaders in cancer research. We’re proud to be part of their journey and look forward to the ideas and energy they bring to our community this summer. @funchainmd.bsky.social

Stanford Cancer Institute @stanford-cancer.bsky.social · Jun 11

We are thrilled to welcome this year’s cohort of five rising second-year medical students from Historically Black Colleges and Universities to our program. These scholars will be paired with Stanford Cancer Institute faculty mentors for an enriching eight-week research experience.

1 4

Pauline Funchain @funchainmd.bsky.social · Jun 4

Wrapping up #ASCO24 with this thought: let’s get more people under the survival curve and lift it up - it might be prolonged survival, it might even be cure. Every moment counts.

May we all walk into our post ASCO lives inspired ✨ 📈 @ascocancer.bsky.social @aspire-cop.bsky.social

Steven Artandi @stevenartandi.bsky.social · May 28

SCI leader @funchainmd.bsky.social & others review treatment strategies for #MetastaticMelanoma: BRAF/MEK inhibitors improve survival; #TILtherapy shows 30% durable response; novel TCR-T & CD3 bispecifics emerging; ICI viable even with irAEs, age, or transplant history.

ascopubs.org

1 2

Pauline Funchain @funchainmd.bsky.social · Jun 3

Melanoma orals #9 ➡️ DANTE trial in 1L metastatic melanoma comparing 1 vs 2 yr anti PD1 + anti CTLA4

➡️ obstacles to accrual, underpowered, stopping at 1 year non inferior*
➡️ no difference in QOL but less concern with staying on treatment

Sarah Danson U Sheffield #ASCO25 @ascocancer.bsky.social

Pauline Funchain @funchainmd.bsky.social · Jun 3

Melanoma orals #8 ➡️ S2000 enco bini nivo vs ipi nivo in symptomatic melanoma brain mets

➡️First randomized trial in symptomatic brain mets
➡️Significant PFS improvement with triple therapy over ipi nivo
➡️No significant OS benefit

Zeynep Eroglu, Moffitt #ASCO25 @ascocancer.bsky.social

1 4

Pauline Funchain @funchainmd.bsky.social · Jun 3

Melanoma orals #7 ➡️ 5 year overall survival from DREAMSEQ

➡️ 63.3% for ipi/nivo first
➡️ 33.9% for dab/tram first

Mike Atkins, Georgetown #ASCO25 @ascocancer.bsky.social

Pauline Funchain @funchainmd.bsky.social · Jun 3

Melanoma orals #7 ➡️ 5 year overall survival from DREAMSEQ

➡️ 63.3% for ipi/nivo first
➡️ 33.9% for dab/tram first

Mike Atkins, Georgetown #ASCO25 @ascocancer.bsky.social

Pauline Funchain @funchainmd.bsky.social · Jun 3

Melanoma orals #6 ➡️ ECOG 6194 ph II pembro + injectable TLR9 agonist vidutolimod in stage III melanoma

pCR 71% MPR 79% 1 yr EFS 89%

Me: pCR much higher than other studies but with an injectable agent very hard to interpret the systemic effect

Ahmad Tarhini #ASCO25 @ascocancer.bsky.social

Pauline Funchain @funchainmd.bsky.social · Jun 3

Melanoma orals #4 ➡️ ph
II neoadjuvant dostarlimab + anti TIM3 cobolimab in stage III melanoma

D+C with mPR 51.9% with 1 yr EFS 92%

Megan Mooradian @mgbresearch.bsky.social #ASCO25 @ascocancer.bsky.social

Pauline Funchain @funchainmd.bsky.social · Jun 3

Melanoma orals #4 ➡️ ph II neadjuvant anti TIGIT tiragolimab and atezolizumab in stage III melanoma
➡️47.7% pCR
➡️91.7% 12 m RFS for those with MPR
➡️no type 1 DM, AI

Tina Heiken @mayocliniccancer.bsky.social
#ASCO25 @ascocancer.bsky.social
@aspire-cop.bsky.social

Pauline Funchain @funchainmd.bsky.social · Jun 3

Caroline Robert asks if we should move away from CTCAE grading of irAE in trials and acknowledge the AI (which she notes is more likely focal hypopit rather than AI) is actually a 6% rate of permanent medication-requiring disease #irAE #ASCO25 #melsm @ascocancer.bsky.social @aspire-cop.bsky.social

Pauline Funchain @funchainmd.bsky.social · Jun 3

Discussion of 1st set of melanoma orals by Ana Arance - Toxicities are the *key* challenge in the adjuvant setting and mitigation of #irAE are the priority in this setting #ASCO25

@ascocancer.bsky.social @aspire-cop.bsky.social

Pauline Funchain @funchainmd.bsky.social · Jun 3

Melanoma orals #3 ➡️ neoadjuvant pembro on stage II/III melanoma

Stage IIC SLN positivity significantly different from historical controls; 2 yr RFS “high”

Me: Intriguing but hard to understand if true impact given a (moving) historical control

Georgios Karakousis
#ASCO25 @ascocancer.bsky.social

Pauline Funchain @funchainmd.bsky.social · Jun 3

Melanoma oral #2 #ASCO25

Ph III adjuvant enco bini - Alex van Akkooi summarizes as a tolerable regimen

@ascocancer.bsky.social

Pauline Funchain @funchainmd.bsky.social · Jun 3

Melanoma oral #1 #ASCO25 ➡️ ph III adj rela nivo vs nivo (RELATIVITY 098) - no difference in RFS, DMFS

Presented by Georgina Long @melanomaau.bsky.social @ascocancer.bsky.social

Reposted by Pauline Funchain

KimberCanada @kimberleybsb.bsky.social · Jun 2

Actually, yes, this and a fantastic set of encyclopedias

720 2.6K 23K

Pauline Funchain @funchainmd.bsky.social · Jun 3

Seeing this picture gave me joy - thank you for being a light in our community! 💙